as 09-06-2024 4:00pm EST
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Founded: | 2003 | Country: | Canada |
Employees: | N/A | City: | MONTREAL |
Market Cap: | 83.1M | IPO Year: | N/A |
Target Price: | $13.00 | AVG Volume (30 days): | 122.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.96 | EPS Growth: | N/A |
52 Week Low/High: | $1.12 - $3.52 | Next Earning Date: | 08-08-2024 |
Revenue: | N/A | Revenue Growth: | -80.00% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
MIST Breaking Stock News: Dive into MIST Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
GlobeNewswire
2 days ago
GlobeNewswire
3 days ago
GlobeNewswire
4 days ago
GlobeNewswire
12 days ago
Associated Press Finance
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
The information presented on this page, "MIST Milestone Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.